Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Free Cash Flow (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Free Cash Flow for 13 consecutive years, with -$6.1 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 456.04% to -$6.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $238.5 million through Dec 2025, up 2110.05% year-over-year, with the annual reading at $238.5 million for FY2025, 2109.77% up from the prior year.
  • Free Cash Flow for Q4 2025 was -$6.1 million at Theravance Biopharma, up from -$6.5 million in the prior quarter.
  • The five-year high for Free Cash Flow was $208.1 million in Q2 2025, with the low at -$71.6 million in Q1 2021.
  • Average Free Cash Flow over 5 years is -$2.2 million, with a median of -$6.3 million recorded in 2025.
  • Peak annual rise in Free Cash Flow hit 4774.77% in 2025, while the deepest fall reached 456.04% in 2025.
  • Over 5 years, Free Cash Flow stood at -$45.7 million in 2021, then soared by 231.84% to $60.2 million in 2022, then tumbled by 102.54% to -$1.5 million in 2023, then increased by 28.67% to -$1.1 million in 2024, then plummeted by 456.04% to -$6.1 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$6.1 million, -$6.5 million, and $208.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.